Subscribe or Manage Preferences
Rheumatology Practice Management June 2017 Vol 5 No 3 - FDA News & Updates
Anne Rowe

In early May 2017, the US Senate voted 57 to 42 to appoint Scott Gottlieb, MD, as the 23rd Commissioner of the FDA. Dr Gottlieb is a physician, medical policy expert, and public health advocate who previously served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs, and as Senior Advisor to the FDA Commissioner. In 2013, he was appointed as a member of the federal Health Information Technology Policy Committee, a group that advises the US Department of Health & Human Services on issues pertaining to healthcare information technology issues. He also served as a Senior Advisor to the Administrator of the Centers for Medicare & Medicaid Services, where he worked on implementing the Medicare drug benefits.

In a recent press statement, American College of Rheumatology (ACR) President Sharad Lakhanpal, MBBS, MD, voiced support for Dr Gottlieb in his new role.

“The ACR congratulates Dr. Scott Gottlieb on his confirmation as FDA Commissioner. As prescribing doctors, rheumatologists share Commissioner Gottlieb’s goal of optimizing FDA biosimilar and generic drug approvals to increase competition, lower costs, and improve our patients’ access to safe and proven therapies,” Dr Lakhanpal said. He also emphasized the importance of adequately funding the FDA to ensure that biosimilars reach the patients who need them.

“The FDA continues to play a critical role in lowering biologic drug costs as it works to bring safe, effective, and lower-cost biosimilar alternatives to the marketplace. Therefore, it is imperative that FDA have the funding and resources it needs to expedite biosimilar drug approvals, hire and retain qualified staff, issue guidance, and perform adequate post-market surveillance,” he stated.

Related Items
Building an Effective Rheumatology Compliance Plan
Anne Rowe
Rheumatology Practice Management December 2017 Vol 6 No 5 published on January 8, 2018 in NORM Conference News
Medical Groups Applaud Congressional Leaders for Bipartisan Agreement to Repeal Medicare Therapy Caps
Anne Rowe
Rheumatology Practice Management December 2017 Vol 6 No 5 published on January 8, 2018 in Health Policy
New Treatments Approved for Patients with Giant-Cell Arteritis and Moderate-to- Severe Rheumatoid Arthritis
Rheumatology Practice Management June 2017 Vol 5 No 3 published on June 28, 2017 in FDA News & Updates
Medical Groups Unite, Call for Prior Authorization Reform
Anne Rowe
Rheumatology Practice Management February 2017 Vol 5 No 1 published on March 2, 2017 in AMA News
American Medical Association Introduces Tools to Help Physicians Prepare for Medicare Payment Reform
Anne Rowe
Rheumatology Practice Management December 2016 Vol 4 No 6 published on December 28, 2016 in Health Policy
Evidence-Based Leadership Model: Achieving Desired Results and Keeping Them
Anne Rowe
Rheumatology Practice Management October 2016 Vol 4 No 5 published on October 28, 2016 in NORM News
FDA Updates - October 2016
Rheumatology Practice Management October 2016 Vol 4 No 5 published on October 28, 2016 in FDA News & Updates
Strategies for Speeding Up Patient Revenue
Anne Rowe
Rheumatology Practice Management October 2016 Vol 4 No 5 published on October 28, 2016 in NORM News
Biosimilar to Etanercept FDA Approved for Inflammatory Diseases
In the News: Practice Management - September 2016 published on September 8, 2016 in FDA News & Updates
FDA Approves Fluciclovine F18 Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer
Urology Practice Management - June 2016, Vol 5, No 3 published on June 20, 2016 in FDA News & Updates
Last modified: July 5, 2017
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management

Search